目的 探討?zhàn)B血清腦丸聯(lián)合苯甲酸利扎曲普坦片治療偏頭痛的臨床療效。方法 選取2019年5月-2020年5月在漯河市中心醫(yī)院就診的118例偏頭痛患者，按照隨機數(shù)字法分為對照組（59例）和治療組（59例）。對照組口服苯甲酸利扎曲普坦片，10 mg/次，3次/d。治療組在對照組基礎(chǔ)上口服養(yǎng)血清腦丸，2.5 g/次，3次/d。兩組患者連續(xù)治療1個月。觀察用藥后的治療效果、臨床癥狀、血流速度指標(biāo)、血清中相關(guān)因子和不良反應(yīng)情況。結(jié)果 治療組治療后的總有效率為93.22%，明顯高于對照組的71.19%（P<0.05）。兩組患者經(jīng)過藥物治療后，頭痛持續(xù)時間評分、頭痛程度評分和頭痛指數(shù)均較治療前明顯改善（P<0.05），且治療組較對照組癥狀明顯減輕（P<0.05）。兩組患者經(jīng)過藥物治療后，大腦前動脈、中動脈、椎動脈、后動脈和基底動脈的血流速度較治療前明顯改善（P<0.05），且治療組的血流速度明顯低于對照組（P<0.05）。兩組患者經(jīng)過藥物治療后，氧化型低密度脂蛋白（ox-LDL）、內(nèi)皮素-1（ET-1）、環(huán)氧合酶2（COX-2）和5-羥色胺（5-HT）較治療后明顯降低（P<0.05），對氧磷酶-1（PON-1）明顯升高（P<0.05），而治療組這些指標(biāo)較對照組明顯改善（P<0.05）。結(jié)論 養(yǎng)血清腦丸聯(lián)合苯甲酸利扎曲普坦片治療偏頭痛總有效率高，能夠緩解臨床癥狀，改善血流速度指標(biāo)，調(diào)節(jié)ox-LDL、ET-1、COX-2、5-HT和PON-1水平，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the therapeutic effect of Yangxue Qingnao Pills combined with rizatriptan monobenzoate in treatment of migraine. Methods Patients (118 case) with migraine in Luohe Central Hospital from May 2019 to May 2020 were randomly divided into control (59 cases) and treatment (59 cases) groups. Patients in the control group were po administered with Rizatriptan Monobenzoate Tablets, 10 mg/time, three times daily. Patients in the treatment group were po administered with Yangxue Qingnao Pills on the basis of the control group, 2.5 g/time, three times daily. Patients in two groups were treated for 1 month. The therapeutic effect, the improvement of clinical symptoms, blood flow velocity index, serum related factors were observed. Results The clincial effective rate of the treatment group after treatment was 93.22%, which was significantly higher than 71.19% of the control group (P<0.05). After treatment, the headache duration, headache degree and headache index in the two groups were significantly improved as compared with those before treatment (P<0.05), and the symptoms in the treatment group were significantly relieved than those in the control group (P<0.05). After treatment, the blood flow velocities of anterior cerebral artery, middle artery, vertebral artery, posterior artery and basilar artery in the two groups were significantly improved as compared with those before treatment (P<0.05), and the blood flow velocity in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, ox-LDL, ET-1, COX-2 and 5-HT in the two groups were significantly decreased (P<0.05), but PON-1 was significantly increased (P<0.05), while these indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Yangxue Qingnao Pills combined with rizatriptan monobenzoate in treatment of migraine has a higher overall efficiency, which can relieve clinical symptoms, improve blood flow velocity indexes, and ox-LDL, ET-1, COX-2, 5-HT and PON-1 levels, which has a certain clinical application value.

R971